ORAL TYPHOID VACCINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The oral typhoid vaccine market size is expected to reach US$ 285.6 Mn by 2030, from US$ 126.8 Mn in 2023, at a compound annual growth rate (CAGR) of 12.3% during the forecast period.

The oral typhoid vaccine market is characterized by the production and distribution of vaccines that are designed to prevent typhoid fever through oral administration. These vaccines are considered effective and convenient in providing immunity against the disease, particularly in regions with a high incidence of typhoid. The key market players include pharmaceutical companies and vaccine manufacturers who develop and distribute these vaccines to healthcare facilities, travel clinics, and vaccination programs. The factors which are driving the market growth include the rising awareness of typhoid prevention, increased travel to typhoid-endemic regions, and government initiatives to control the disease. However, challenges such as vaccine availability, affordability, and accessibility in low-income regions remain significant concerns within the oral typhoid vaccine market. Continuous research and development (R&D) efforts are aimed at improving vaccine efficacy and expanding its global reach.

Oral Typhoid Vaccine Market Regional Insights:

• North America is the second largest market for oral typhoid vaccines which is estimated to account for a market share of 27.4% in 2023. The growth of the market in this region is due to  the increasing incidence of typhoid fever, rising awareness about the benefits of vaccination, and increasing government initiatives to promote vaccination.
• Asia Pacific is the largest market for oral typhoid vaccines which is estimated to account for a market share of 42.6% in 2023. The growth of the market in this region is due to the high incidence of typhoid fever, increasing awareness about the benefits of vaccination, and rising disposable income of people in developing countries.
• Europe is estimated to account for a market share of 19.8% in 2023. The growth of the market in this region is due to the increasing incidence of typhoid fever, rising awareness about the benefits of vaccination, and increasing government initiatives to promote vaccination.

Figure 1.  Oral Typhoid Vaccine Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Analysts’ Views on Oral Typhoid Vaccine Market:

The oral typhoid vaccine market growth is driven by the increasing prevalence of typhoid fever in regions with poor sanitation and hygiene, and the growing emphasis on preventive healthcare. These factors have increased the demand for oral typhoid vaccines, which offer a convenient and effective means of protection against the disease. The government immunization programs in endemic regions drive the oral typhoid vaccine market growth.

However, restraints exist, such as the need for a cold chain for vaccine storage, which can be challenging in resource-limited settings. The market also faces competition from injectable typhoid vaccines. Addressing these challenges through improved distribution, and awareness campaigns will be vital for ensuring the broader adoption and effectiveness of oral typhoid vaccines. The market's future will depend on overcoming these barriers while capitalizing on the growing awareness of the vaccine's importance in typhoid-endemic regions.

Oral Typhoid Vaccine Market Drivers:

• Growing awareness about the benefits of vaccination: There is a growing awareness about the benefits of vaccination against typhoid fever. People are becoming more aware of the risks of typhoid fever and the importance of vaccination to protect themselves and their families.
• Rising disposable income of people in developing countries: The disposable income of people in developing countries is rising. This is leading to an increase in the demand for healthcare products and services, including vaccines.
• Increasing government initiatives to promote vaccination: Governments in many developing countries are increasing their efforts to promote vaccination against typhoid fever. This is being done through public awareness campaigns, school-based vaccination programs, and other initiatives.

Oral Typhoid Vaccine Market Opportunities:

• Expanding immunization programs in developing countries: Many developing countries are expanding their immunization programs to include typhoid fever vaccination. This is being done in response to the increasing incidence of typhoid fever in these countries.
• Increasing demand for typhoid vaccines from travelers: There is an increasing demand for typhoid vaccines from travelers. This is due to the fact that typhoid fever is a common disease in many parts of the world, and travelers may be at risk of contracting the disease.
• Diversification of product offerings: Developing a broader range of oral typhoid vaccine products, including improved formulations and combination vaccines, can cater to different population groups and enhance market penetration.
• Growing demand for personalized medicine: Personalized medicine is a field of medicine that takes into account individual patient characteristics to customized treatment. This is becoming increasingly important in the field of vaccination, as researchers are developing vaccines that are tailored to specific populations. The growing demand for personalized medicine is expected to create new opportunities for the oral typhoid vaccine market.

Oral Typhoid Vaccine Market Trends:

• Government vaccination programs: Many governments are implementing mass vaccination campaigns to control typhoid outbreaks, thus driving the adoption of oral typhoid vaccines.
• Growing demand for needle-free vaccines: There is a growing demand for needle-free vaccines. This is due to the fact that needle-free vaccines are more convenient and less painful than traditional vaccines. The growing demand for needle-free vaccines is expected to create new trends in the oral typhoid vaccine market.

Oral Typhoid Vaccine Market Restraints:

• Limited access in low-income regions: Many low-income regions with a high burden of typhoid, lack access to oral typhoid vaccines due to issues related to affordability, distribution, and healthcare infrastructure.
• Cold chain requirements: Oral typhoid vaccines often require specific temperature-controlled storage and transportation, posing logistical challenges, especially in remote or underserved areas with inadequate cold chain facilities.
• Vaccine hesitancy: Vaccine hesitancy, fueled by misinformation and concerns about vaccine safety, can hinder vaccine acceptance and uptake among certain populations.

Counterbalance: The oral typhoid vaccine should be made affordable for the people in the low-income regions by offering it at a reasonable price and adequate accessibility. Also, programs to make people aware about the importance of vaccine needs to be undertaken by removing misinformation about the same.

Recent Developments:

• In March 2020, Daewoong Pharmaceutical, a South Korea-based pharmaceutical company, launched the Vivotif, an oral typhoid fever vaccine, in the local market.
• In February 2023, Bavarian Nordic, a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines, announced acquisition of typhoid fever vaccine, Vivotif, and its cholera shot, Vaxchora, alongside the late-stage chikungunya candidate CHIKV VLP.

Figure 2.  Oral Typhoid Vaccine Market Share (%), By Distribution Channel, 2023

To learn more about this report, request sample copy

Top Companies in Oral Typhoid Vaccine Market:

• Janssen Global Services, LLC
• EMERGENT
• Berna Biotech AG
• Daewoong Pharmaceutical
• Bavarian Nordic

Definition: The oral typhoid vaccine market refers to the commercial segment of the healthcare industry involved in the production, distribution, and sale of vaccines that are administered orally to prevent typhoid fever which is a bacterial infection caused by Salmonella typhi. These vaccines are designed to stimulate the body's immune response and provide immunity against the typhoid bacterium when ingested orally, particularly in regions with a high prevalence of the disease or for travelers visiting typhoid-endemic areas.